EW as reported
Edwards Lifesciences reported $6.51B of revenue over the trailing twelve months, +15% on the year before. 11 reported series are charted on this page, each one as filed.
$6.51B
Revenue, trailing twelve months · to Q2 2026 · +15% against the twelve months before
- Net Income
- $1.00B
Net Income · −76% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $1.43B
Free Cash Flow · +144% year on year · trailing twelve months to Q2 2026
- Op Margin
- 22%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $6.51B | +15% | Q2 2026 |
| Net Income | $1.00B | −76% | Q2 2026 |
| EPS | $1.74 | −75% | Q2 2026 |
| Gross Margin | 78% | n/a | Q2 2026 |
| Op Margin | 22% | n/a | Q2 2026 |
| Net Margin | 15% | n/a | Q2 2026 |
| ROE | 11% | n/a | Q2 2026 |
| ROA | 8.4% | n/a | Q2 2026 |
| ROIC | 16% | n/a | Q2 2026 |
| Free Cash Flow | $1.43B | +144% | Q2 2026 |
| P/E | 52.2 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Edwards Lifesciences (EW) - Revenue & ProfitRevenue & ProfitEdwards Lifesciences (EW)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Devices
Ranks #18 of 35 by Smart Score